MSD’s Lipfendra takes on injectable rivals for cholesterol-lowering market supremacy
Filling a Keytruda-sized sales void was always going to be challenging, but Merck & Co (MSD) may have crafted a…
27 Aug 2026
MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones
The US policy of Most Favoured Nation (MFN) pricing has raised uncertainty in European markets reluctant to raise drug prices and driven a debate among Europe’s smaller countries around whether…
24 Aug 2026
A strategic shift for gene therapies: manufacturing and market size take centre stage
Despite fostering cutting-edge science, gene therapy biotechs have sometimes failed to reach commercial heights due to inherent scalability hurdles. Consequently, the sector has faced dwindling investor sentiment in recent years.…
11 Aug 2026
Health tech’s role in obesity to expand beyond a ‘nice-to-have’
In recent years, there has been a sharp focus on treating obesity and its associated comorbidities, as the World Health Organization (WHO) estimates that one billion people globally live with…
05 Aug 2026
Orexin receptor agonists set to propel narcolepsy treatment into a new era
Note: A few hours after this article was published, oveporexton was approved as a treatment for narcolepsy type 1. More details can be found here. A decision on the highly…
31 Jul 2026
Boosting CGT access: a global consideration with wide-spanning benefits
Back in 2014, Jonathan Clark’s world was flipped on its head when he was diagnosed with mantle cell lymphoma (MCL) at age 52. While Clark began receiving treatment soon after…
27 Jul 2026
Magazine: Made in the USA
A combination of US government incentives, supply chain disruptions, and geopolitical tensions are prompting increased investment in US manufacturing. In this month's cover story, we spoke to Misumi Americas CEO…